Forum Topic News
  • Conversation: Boehringer Ingelheim and OSE Immunotherapeutics announce global immuno-oncology partnership to develop a pioneering checkpoint inhibitor for the treatment of advanced solid tumors

    • April 6, 2018 12:39 PM BST
    • Boehringer Ingelheim and OSE Immunotherapeutics announce global immuno-oncology partnership to develop a pioneering checkpoint i...

      Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.
      SIRP-alpha is a receptor expressed by myeloid lineage cells such as Dendritic Cells (DCs), tumor-associated macrophages (TAMs) and Myeloid-Derived Suppressor Cells (MDSCs). In targeting SIRP- alpha, OSE-172 prevents the ligand CD47 from binding to and triggering the cellular inhibitory effects of SIRP-alpha. OSE-172 has the potential to enhance anti-tumor immunity by improving T cell activity through enhancement of DC antigen presentation functionality, potentiating the phagocytic and inflammatory properties of macrophages in the tumor microenvironment and enabling differentiation of MDSCs to an effector state.
      Read more: http://www.worldpharmanews.com/boehringer-ingelheim/4352-boehringer-ingelheim-and-ose-immunotherapeutics-announce-global-immuno-oncology-partnership-to-develop-a-pioneering-checkpoint-inhibitor-for-the-treatment-of-advanced-solid-tumors

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč